Loading organizations...
Key people at Cencora Ventures.
Cencora Ventures operates as the strategic corporate venture capital arm of Cencora, the global healthcare solutions enterprise. This fund actively invests in and partners with entrepreneurial businesses that are developing groundbreaking solutions aimed at advancing the future of human and animal healthcare. Its focus lies on fostering innovation across the healthcare ecosystem, leveraging Cencora's extensive reach and expertise.
The venture fund originated as AB Health Ventures under AmerisourceBergen, undergoing a rebranding to Cencora Ventures in alignment with its parent company's transition to the unified Cencora identity. This evolution reflects a strategic commitment by Cencora to actively participate in and accelerate the development of next-generation healthcare technologies and services. The initiative stems from the insight that external innovation is critical to complementing internal efforts and addressing complex healthcare challenges.
The fund's primary beneficiaries are the emerging companies and visionary entrepreneurs it supports, providing them with capital and strategic guidance to scale their innovations. Cencora Ventures envisions a future where accessible and effective healthcare solutions are ubiquitous, driven by continuous innovation. Its long-term mission is to create healthier futures globally by cultivating a portfolio of companies poised to redefine health outcomes.
Key people at Cencora Ventures.
Cencora Ventures has 4 tracked investments across 4 companies. The latest tracked deal is $19.0M Series A in NexCure in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 5, 2026 | NexCure | $19.0M Series A | RA Capital Management | Oncology Ventures |
| Mar 5, 2025 | Lumata Health | $23.0M Series B | Cencora Ventures, Lrvhealth, McKesson Ventures | — |
| May 12, 2024 | Acclinate | $7.0M Series A | Cencora Ventures | Labcorp, Latimer Ventures |
| May 1, 2024 | Atropos Health | $33.0M Series B | Mike Spadafore | Bluecross Blueshield Venture Partners, CVS Health, OAK HC/FT, Sandbox Industries, Breyer Capital, Emerson Collective, Michelle Snyder, Merck, Presidio Ventures |